**Rubicon Research IPO Subscribed 48 Times on Final Day**
*By Mudit Dube | Oct 13, 2025, 04:23 PM*
Rubicon Research, a pharmaceutical formulation company with a strong focus on R&D and innovation, has seen its Initial Public Offering (IPO) subscribed 48 times on the third and final day of bidding today. According to data from the National Stock Exchange (NSE), the company received bids for over 179.32 crore shares against 1.64 crore shares on offer.
### IPO Details and Investor Participation
The IPO, priced within a band of ₹461-485 per share, will close today. It comprises a fresh issue of equity shares worth ₹500 crore along with an Offer For Sale (OFS) of ₹877.5 crore by promoter General Atlantic Singapore RR Pte Ltd.
Investor participation has been very strong across categories. The Retail Individual Investors (RIIs) quota was subscribed 26 times, the Non-Institutional Investors category saw an overwhelming subscription of 80.07 times, and the Qualified Institutional Buyers (QIBs) quota was subscribed 39.84 times.
On Wednesday, Rubicon Research announced that it had mobilized ₹619 crore from anchor investors for its IPO. Kotak Mutual Fund and Motilal Mutual Fund have together invested approximately ₹169 crore in the pharmaceutical company.
### Plans for IPO Proceeds and Shareholding Impact
Rubicon Research intends to utilize the proceeds from the fresh equity issue primarily for debt repayment, inorganic growth through acquisitions, strategic initiatives, and general corporate purposes.
Following the IPO, the shareholding of General Atlantic is expected to reduce to just over 35%.
### About Rubicon Research
Rubicon Research operates as a pharmaceutical formulation company with a robust commitment to research and development. The company has been actively expanding its manufacturing footprint, most recently acquiring Alkem Laboratories’ formulations facility in Pithampur, Madhya Pradesh, for ₹149 crore in an all-cash deal.
The firm boasts two US FDA-inspected R&D centers—one in India and another in Canada—and operates two manufacturing plants in India accredited by several regulatory authorities, including the USFDA, Maharashtra FDA (WHO-GMP), and Health Canada.
—
Rubicon Research’s strong IPO response reflects significant investor confidence in its business prospects and pharmaceutical innovation capabilities.
https://www.newsbytesapp.com/news/business/rubicon-research-ipo-day-3-subscription-status-and-latest-gmp/story
